← Human Trials & Peer-Reviewed Studies
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Plain-language guide to PMID 38599221 (2024): double-blind randomized controlled trial study of Semaglutide.
Key Facts
- PMID
- 38599221
- Journal
- Lancet (London, England)
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Butler J et al. (32 authors)
- DOI
- 10.1016/S0140-6736(24)00469-0
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Semaglutide.
In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, the researchers aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
The researchers conducted a prespecified pooled analysis of individual patient data from STEP-HFpEF and STEP-HFpEF DM, randomised, double-blind, placebo-controlled trials at 129 clinical research sites in 18 countries.
The dual primary endpoints were change from baseline to week 52 in KCCQ-CSS and bodyweight in all randomly assigned participants.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.
As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Semaglutide group a baseline to be compared against.
Heterogeneity in treatment effects was assessed across subgroups of interest.
What Was Measured
The subject headings attached to it are Heart Failure, Glucagon-Like Peptides, Stroke Volume, Obesity and Semaglutide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Semaglutide.
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (Lancet (London, England)), a journal based in England.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.